Compare VERX & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERX | AAPG |
|---|---|---|
| Founded | 1978 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.6B |
| IPO Year | 2020 | N/A |
| Metric | VERX | AAPG |
|---|---|---|
| Price | $12.83 | $24.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 6 |
| Target Price | $28.29 | ★ $48.40 |
| AVG Volume (30 Days) | ★ 1.9M | 1.8K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $748,444,000.00 | N/A |
| Revenue This Year | $12.78 | N/A |
| Revenue Next Year | $11.61 | $368.64 |
| P/E Ratio | $302.25 | ★ N/A |
| Revenue Growth | ★ 12.25 | N/A |
| 52 Week Low | $11.87 | $17.56 |
| 52 Week High | $42.44 | $48.45 |
| Indicator | VERX | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 35.23 | 47.83 |
| Support Level | $11.91 | $23.12 |
| Resistance Level | $15.80 | $25.47 |
| Average True Range (ATR) | 0.62 | 0.76 |
| MACD | -0.01 | 0.20 |
| Stochastic Oscillator | 1.17 | 66.35 |
Vertex Inc is a provider of tax technology and services. Its software, content, and services help customers stay in compliance with indirect taxes that occur in taxing jurisdictions all over the world. It provides cloud-based and on-premise solutions to specific industries for every line of tax, including income, sales, consumer use, value-added, and payroll. The company offers solutions such as tax determination, Tax Data Management, document management, and compliance and reporting, among others. The company derives revenue from software subscriptions.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.